How to Read Your Pharmacogenomic Report: A Plain-Language Guide for Malaysians
pro Genome
TL;DR
A pharmacogenomic report tells you how your genes affect how your body processes medications. It does not tell you to stop or start any medication — that decision belongs to your doctor or pharmacist. This guide explains what each section of a pharmacogenomic report means, what the colour codes and gene names refer to, and how to use the report in a real conversation with your healthcare provider.
Why Reading Your Report Matters
Getting your DNA results back is exciting. It is also, for most people, immediately confusing.
You open the report and see gene names like CYP2D6, CYP2C19, VKORC1. You see classifications like "poor metaboliser" or "intermediate metaboliser." You see green, yellow, and red colour codes next to medication names you recognise — and some you have been taking for years.
This is normal. Pharmacogenomic reports are written for healthcare professionals first and patients second. Without context, the results can feel alarming or meaningless in equal measure.
This guide walks you through exactly what your report is telling you — section by section, in plain language.
What a Pharmacogenomic Report Is — and Is Not
Before reading your results, understand what the report can and cannot tell you.
What it can tell you:
- How your genes are likely to affect how your body breaks down specific medications
- Whether you are likely to process a medication faster, slower, or typically compared to the general population
- Whether you may need a higher or lower dose than standard guidelines suggest
- Whether you carry genetic variants associated with increased risk of side effects from certain drugs
What it cannot tell you:
- Whether you should take or stop any specific medication
- What your diagnosis is
- That a medication will definitely work or definitely cause side effects — genetics is one factor among many
- Anything about medications not covered in the test panel
A pharmacogenomic report is a tool for your doctor and pharmacist to use alongside your medical history, current prescriptions, and clinical judgment. It does not replace that judgment.
Section 1: Your Metaboliser Status — What It Means
The most important concept in any pharmacogenomic report is metaboliser status. This tells you how quickly your body breaks down a specific medication using a specific enzyme.
Most reports classify you into one of four categories:
Poor Metaboliser Your body breaks down this medication very slowly. The drug stays in your system longer and at higher concentrations than expected. This can mean a standard dose feels too strong, side effects are more pronounced, or the medication accumulates to potentially harmful levels over time.
Intermediate Metaboliser Your body processes this medication more slowly than average, but not as slowly as a poor metaboliser. You may need a slightly adjusted dose, or your doctor may want to monitor you more closely.
Normal Metaboliser (also called Extensive Metaboliser) Your body processes this medication at the expected rate. Standard dosing guidelines are likely to apply to you.
Rapid or Ultrarapid Metaboliser Your body breaks down this medication very quickly — faster than expected. The drug may clear your system before it has time to work effectively. A standard dose may produce little to no therapeutic effect. You may need a higher dose, or in some cases, a different medication entirely.
Important: None of these categories is inherently good or bad. They simply describe your genetic baseline. A poor metaboliser for one drug may be a normal metaboliser for another. Your status varies by gene and by medication.
Section 2: The Gene Names — What They Are
Pharmacogenomic reports reference specific genes responsible for drug metabolism. The names look intimidating but each one corresponds to a specific enzyme your liver uses to process medications.
Here are the most commonly referenced genes and what they cover:
CYP2D6 One of the most important drug-metabolising genes. Affects how your body processes antidepressants, antipsychotics, certain heart medications, pain medications including codeine, and some beta-blockers. Approximately 7–10% of people are poor metabolisers for CYP2D6.
CYP2C19 Affects how your body processes proton pump inhibitors (for acid reflux), certain antidepressants, antifungals, and the blood thinner clopidogrel. In Asian populations — including Malaysian Chinese, Malay, and Indian groups — a higher proportion of people carry CYP2C19 variants compared to Western populations. This is one of the key reasons a Malaysian-validated genomic reference is important.
CYP2C9 Affects metabolism of warfarin (a common blood thinner), certain diabetes medications, and some anti-inflammatory drugs. Variants in CYP2C9 are among the most clinically significant because warfarin has a narrow therapeutic window — small dosing errors carry real risk.
VKORC1 Works alongside CYP2C9 to determine warfarin sensitivity. Most warfarin dosing algorithms in clinical use today factor in both CYP2C9 and VKORC1 results together.
CYP3A4 / CYP3A5 Responsible for metabolising the largest proportion of medications currently in use — estimates suggest up to 50% of all drugs are processed through this pathway. Affects statins, calcium channel blockers, immunosuppressants, and many others.
SLCO1B1 Affects how statins (cholesterol-lowering medications) are transported into the liver. Variants in SLCO1B1 are associated with an increased risk of statin-induced muscle pain — a side effect that causes many patients to stop their medication unnecessarily when the genetic basis is not known.
DPYD Relevant for patients receiving certain chemotherapy agents. Variants in DPYD affect how the body breaks down fluoropyrimidine-based chemotherapy drugs. Poor metabolisers face significantly increased toxicity risk.
Section 3: The Colour Codes — Green, Yellow, Red
Most pharmacogenomic reports use a traffic light system to summarise clinical guidance for each medication. Here is what each colour typically means:
Green — Use as directed Your genetic profile suggests standard dosing guidelines are likely to apply. No genetic contraindication identified for this medication based on the genes tested.
Yellow — Use with caution / Consider adjustment Your genetic profile suggests you may respond differently from the average patient. Your doctor or pharmacist should review this result alongside your current prescription. A dose adjustment or additional monitoring may be appropriate.
Red — Significant genetic interaction identified Your genetic profile suggests a clinically significant interaction between your genes and this medication. This does not mean the medication is dangerous for you — it means your prescribing doctor should be aware of this finding before continuing or initiating this medication. A therapeutic alternative may be worth considering.
Note: Colour codes vary slightly between different report providers. Always read the legend in your specific report rather than assuming a universal standard.
Section 4: Nutrigenomic Results — Reading the Nutrition Panel
If your test includes a nutrigenomic (NGx) panel, this section will tell you how your genes affect your ability to absorb and utilise specific nutrients.
Common findings and what they mean:
Vitamin D — Reduced absorption tendency Some people carry variants in the VDR and GC genes that reduce how efficiently their body absorbs Vitamin D from sunlight and diet. If your report flags this, it does not mean you are deficient — it means you may need higher dietary intake or supplementation to reach the same blood level as someone without this variant. Your doctor can confirm with a blood test.
Omega-3 — Reduced conversion efficiency The FADS1 and FADS2 genes affect how efficiently your body converts plant-based Omega-3 (ALA) into the forms your body actually uses (EPA and DHA). If your conversion efficiency is flagged as reduced, marine-sourced Omega-3 supplements (fish oil) are more effective for you than flaxseed-based alternatives.
Lactose intolerance — Genetic predisposition The LCT gene determines whether your body continues producing lactase (the enzyme that breaks down lactose) into adulthood. A genetic predisposition does not guarantee symptoms — but it explains why some people experience digestive discomfort from dairy while others do not.
Caffeine metabolism — Fast or slow The CYP1A2 gene affects how quickly you metabolise caffeine. Slow metabolisers who consume high amounts of caffeine have been associated in some studies with increased cardiovascular risk. Fast metabolisers clear caffeine quickly and are less likely to experience sleep disruption from afternoon coffee.
Obesity and Type 2 Diabetes risk markers These sections reflect genetic risk indicators — not diagnoses. A higher genetic risk score means you may be more susceptible to these conditions under certain lifestyle conditions. It is actionable information for prevention, not a prediction that the condition will develop.
Section 5: How to Use Your Report in a Conversation With Your Doctor or Pharmacist
This is the section most people skip — and it is the most important one.
Your pharmacogenomic report is most valuable when it is reviewed by a healthcare professional who knows your full medical history. Here is how to make that conversation as productive as possible.
Bring your full medication list Write down every medication you are currently taking, including the dose and how long you have been on it. Include supplements and over-the-counter medications. Your pharmacist or doctor will cross-reference this against your report findings.
Ask specifically about any yellow or red flagged medications For each yellow or red result, ask: "Given my genetic profile, is my current dose appropriate? Is there anything we should monitor more closely? Is there an alternative we should consider?"
Ask about medications you may need in the future If you have a family history of heart disease, diabetes, or mental health conditions, ask your pharmacist which relevant medications in those categories your report covers — and what your genetic profile suggests about them.
Do not make any medication changes based on the report alone This cannot be stated strongly enough. Never stop, reduce, or change any medication based on your genomic report without first discussing it with your prescribing doctor or pharmacist. The report is one input — not a prescription.
Keep a copy permanently Your DNA does not change. Your pharmacogenomic report is a lifetime reference document. Store a digital copy somewhere accessible — you may need it years from now when a new medication is prescribed.
Frequently Asked Questions: Understanding Your Pharmacogenomic Report
Q: My report says I am a poor metaboliser for CYP2D6. Should I stop my antidepressant? A: No. Do not stop any medication based on your report alone. Bring this finding to your prescribing doctor or pharmacist. Being a poor metaboliser means your body clears this medication more slowly than average — your doctor may want to review your current dose or monitor you more closely, but this is a clinical decision, not one you should make independently.
Q: My report shows green for all my medications. Does that mean I have no issues? A: Green means no significant genetic interaction was identified for the genes tested. It does not mean the medication is perfect for you in every respect — other factors like kidney function, age, weight, and drug interactions still apply. Discuss your results with your pharmacist even if everything shows green.
Q: Why does my report mention genes I have never heard of? A: The gene names in pharmacogenomic reports — CYP2D6, CYP2C19, VKORC1 and others — refer to enzymes in your liver that process medications. They are named according to international scientific convention. Your report should include a glossary or your genomic counsellor can walk you through each one during your consultation.
Q: My family member has the same condition as me. Will their pharmacogenomic report look the same? A: Not necessarily. Even within the same family, genetic variants are distributed differently. Siblings share approximately 50% of their genetic variants on average. Your pharmacogenomic profile is yours alone.
Q: Can my pharmacogenomic report predict whether a new medication will work? A: It can indicate how your body is likely to metabolise that medication based on your genetic profile. This is clinically useful information — but drug response also depends on the condition being treated, other medications you are taking, your overall health, and other factors. Your report narrows the uncertainty; it does not eliminate it.
Q: How often should I re-do a pharmacogenomic test? A: Your DNA does not change, so you do not need to repeat the test. However, as genomic science advances, the interpretation of existing variants may be updated. This is one reason why lifetime consultation access — where your healthcare provider can revisit your results in light of new clinical guidelines — is valuable.
Q: Is a pharmacogenomic report the same as a genetic disease test? A: No. A pharmacogenomic report analyses variants that affect drug metabolism — it is not a diagnostic test for genetic diseases. Some reports include general risk markers for conditions like certain cancers, but these are risk indicators, not diagnoses. If you have concerns about inherited disease risk, speak to a genetic counsellor.
About pro.Genome
pro.Genome is a pharmacogenomic and nutrigenomic DNA test available at Alpro Pharmacy and Alpro Clinic outlets across Malaysia. It covers 287 medication response traits using Next-Generation Sequencing (NGS) technology, is processed at AGTC Genomics — an ISO-certified, PDPA-compliant Malaysian laboratory — and includes lifetime one-on-one consultation with doctors, pharmacists, dietitians, and nutritionists to help you understand and act on your results.
Visit progenome2u.com or your nearest Alpro Pharmacy or Alpro Clinic to learn more.
